693 related articles for article (PubMed ID: 25987051)
21. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
24. High Expression of Serum UCA1 may be a Potential Biomarker for Clinical Diagnosis of Gastric Cancer.
Shan L; Liu C; Ma C
Clin Lab; 2019 Sep; 65(9):. PubMed ID: 31532112
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Serum CA72-4 and CEA Levels in Patient with Endoscopically Suspected Gastric Carcinoma.
Rehena Z; Ghosh CK; Afroz F; Alam MB; Ferdousi S; Mahmuduzzaman M; Sultana T; Ahmed AN
Mymensingh Med J; 2015 Jul; 24(3):542-9. PubMed ID: 26329953
[TBL] [Abstract][Full Text] [Related]
26. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
[TBL] [Abstract][Full Text] [Related]
27. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
28. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer.
Jing R; Cui M; Ju S; Pan S
Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307
[TBL] [Abstract][Full Text] [Related]
29. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.
Qiu Y; He J; Chen X; Huang P; Hu K; Yan H
Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681
[TBL] [Abstract][Full Text] [Related]
31. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
32. Value of combined serum CEA, CA72-4, and CA19-9 marker detection in diagnosis of colorectal cancer.
Kildusiene I; Dulskas A; Smailyte G
Tech Coloproctol; 2024 Feb; 28(1):33. PubMed ID: 38358422
[TBL] [Abstract][Full Text] [Related]
33. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.
Pan YQ; Ruan YY; Peng JB; Han QY; Zhang X; Lin A; Yan WH
Hum Immunol; 2016 Apr; 77(4):317-24. PubMed ID: 26788811
[TBL] [Abstract][Full Text] [Related]
35. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading.
Ghaderi B; Moghbel H; Daneshkhah N; Babahajian A; Sheikhesmaeili F
J Gastrointest Cancer; 2019 Sep; 50(3):525-529. PubMed ID: 29806060
[TBL] [Abstract][Full Text] [Related]
36. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma.
Qiu MZ; Lin JZ; Wang ZQ; Wang FH; Pan ZZ; Luo HY; Li YH; Zhou ZW; He YJ; Xu RH
Int J Biol Markers; 2009; 24(4):258-64. PubMed ID: 20082274
[TBL] [Abstract][Full Text] [Related]
37. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control.
Shang X; Song C; Du X; Shao H; Xu D; Wang X
Saudi Med J; 2017 Feb; 38(2):204-208. PubMed ID: 28133696
[TBL] [Abstract][Full Text] [Related]
38. Advances in Molecular Biomarkers for Gastric Cancer.
Zheng TH; Zhao JL; Guleng B
Crit Rev Eukaryot Gene Expr; 2015; 25(4):299-305. PubMed ID: 26559090
[TBL] [Abstract][Full Text] [Related]
39. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?
Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P
Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]